Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.

Latimer, Nicholas R; Abrams, Keith R; Amonkar, Mayur M; Stapelkamp, Ceilidh; Swann, R Suzanne

Latimer, Nicholas R; Abrams, Keith R; Amonkar, Mayur M; Stapelkamp, Ceilidh; Swann, R Suzanne.

Afiliação

Latimer NR; School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom; Department of Health Sciences, University of Leicester, Leicester, United Kingdom; GlaxoSmithKline, Collegeville, Pennsylvania, USA; GlaxoSmithKline, Uxbridge, United Kingdom n.latimer@sheffield.ac.uk.
Abrams KR; School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom; Department of Health Sciences, University of Leicester, Leicester, United Kingdom; GlaxoSmithKline, Collegeville, Pennsylvania, USA; GlaxoSmithKline, Uxbridge, United Kingdom.
Amonkar MM; School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom; Department of Health Sciences, University of Leicester, Leicester, United Kingdom; GlaxoSmithKline, Collegeville, Pennsylvania, USA; GlaxoSmithKline, Uxbridge, United Kingdom.
Stapelkamp C; School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom; Department of Health Sciences, University of Leicester, Leicester, United Kingdom; GlaxoSmithKline, Collegeville, Pennsylvania, USA; GlaxoSmithKline, Uxbridge, United Kingdom.
Swann RS; School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom; Department of Health Sciences, University of Leicester, Leicester, United Kingdom; GlaxoSmithKline, Collegeville, Pennsylvania, USA; GlaxoSmithKline, Uxbridge, United Kingdom.

Oncologist ; 20(7): 798-805, 2015 Jul.

Article em En | MEDLINE | ID: mdl-26040620

Assuntos

Dacarbazina/uso terapêutico; Imidazóis/uso terapêutico; Melanoma/tratamento farmacológico; Oximas/uso terapêutico; Proteínas Proto-Oncogênicas B-raf/genética; Adulto; Idoso; Antineoplásicos/uso terapêutico; Antineoplásicos Alquilantes/uso terapêutico; Intervalo Livre de Doença; Feminino; Humanos; Estimativa de Kaplan-Meier; Masculino; Melanoma/genética; Melanoma/mortalidade; Melanoma/patologia; Pessoa de Meia-Idade; Mutação; Resultado do Tratamento

Palavras-chave

BRAF V600E mutation-positive melanoma; Dabrafenib; Dacarbazine; Overall survival; Survival analysis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oximas / Dacarbazina / Proteínas Proto-Oncogênicas B-raf / Imidazóis / Melanoma Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google